{"id":"adl5859","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL494480","moleculeType":"Small molecule","molecularWeight":"392.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADL5859 works by inhibiting the enzyme transpeptidase, which is essential for bacterial cell wall formation. This leads to the disruption of the bacterial cell wall, ultimately causing cell lysis and death. ADL5859 has shown promise in treating various bacterial infections.","oneSentence":"ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:40.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated urinary tract infections"},{"name":"Complicated intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT00979953","phase":"PHASE2","title":"Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-10","conditions":"Osteoarthritis of the Knee","enrollment":408},{"nctId":"NCT00993863","phase":"PHASE2","title":"Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-06","conditions":"Acute Pain","enrollment":201},{"nctId":"NCT00603265","phase":"PHASE2","title":"Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-11","conditions":"Peripheral Neuropathy, Neuropathic Pain","enrollment":226},{"nctId":"NCT00626275","phase":"PHASE2","title":"Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ADL-5859"],"phase":"phase_2","status":"active","brandName":"ADL5859","genericName":"ADL5859","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ADL5859 is a small molecule antibiotic that targets the bacterial cell wall synthesis. Used for Complicated urinary tract infections, Complicated intra-abdominal infections.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}